What is ICD-10 code D70.2?

D70.2 is the ICD-10-CM diagnosis code for Other drug-induced agranulocytosis. A low white blood cell count caused by medications other than chemotherapy drugs. It belongs to the ICD-10-CM chapter for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (d50-d89). D70.2 is a billable code, meaning it can be reported on a claim as a primary or secondary diagnosis when supported by documentation. D70.2 is part of the FY2026 ICD-10-CM code set published by the CMS National Center for Health Statistics and used on Medicare, Medicaid, and commercial claims in the United States.

Yes. D70.2 is a billable ICD-10-CM code that can be reported on professional and institutional claims as a primary or secondary diagnosis when the provider documentation supports the specific condition described. Billable codes in ICD-10-CM are coded to the highest level of specificity available for the documented diagnosis. D70.2 is current for fiscal year 2026 and remains in the active CMS ICD-10-CM code set published by the National Center for Health Statistics.

Which HCC does D70.2 map to under V28?

D70.2 has no payable CMS-HCC V28 mapping in the final FY2026 CMS file.

What RAF reference is published for D70.2?

D70.2 has no V28 reference coefficient because the final FY2026 source verifies no payable V28 mapping.

What is the V28 vs V24 difference for D70.2?

D70.2 has verified no payable V28 mapping in the final FY2026 source. Select a historical effective period before making any V24 comparison.

What documentation supports D70.2?

Document the specific medication causing the agranulocytosis in the medical record for clarity Differentiate from D70.1 (chemotherapy-induced) by confirming the offending drug is not a cancer treatment D70.2 is not a CMS-HCC V28 payment code in the verified current source, so MEAT is not the payment hook. Documentation still has to support the diagnosis if you report it.

2026 ICD-10-CM D70.2: Other drug-induced agranulocytosis

D70.2 is not a CMS-HCC payment code. MEAT criteria · RAF Calculator · HCC Buddy coding tools

ICD-10-CM Code View

HCC Buddy Code Card

Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.

Code lookupD70.2

Effective periodFY2026 Apr Update (Apr 1-Sep 30)

FY 2026 Apr update / Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89) / Other disorders of blood and blood-forming organs (D70-D77)

D70.2

Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidance

Other drug-induced agranulocytosis

A low white blood cell count caused by medications other than chemotherapy drugs.

Buddy Insight

Overview Risk Models Code Book Documentation Audit Notes Edition comparison

CMS-HCC V28

N/A

—

Not risk-adjusted for this model/period.

Not mapped

CMS-HCC V24

Historical

Not used for standard CY2026 Medicare Advantage payment. Select a historical period to review V24.

Not used for CY2026 payment

ACA/HHS

N/A

—

Not risk-adjusted for this model/period.

Not mapped

ESRD/PACE

Mapped

HCC 47

Disorders of Immunity

Code-level coefficient reference

RXHCC

N/A

—

Not risk-adjusted for this model/period.

Not mapped

Code Book Path

Official

D70Neutropenia D70.2Other drug-induced agranulocytosis

Inclusion Terms

Official

No inclusion terms are included in this display for D70.2. Check the code and parent instructions in the Code Book.

Excludes 2

Official

autoimmune disease (systemic) NOS (M35.9)Inherited from D50-D89
certain conditions originating in the perinatal period (P00-P96)Inherited from D50-D89
complications of pregnancy, childbirth and the puerperium (O00-O9A)Inherited from D50-D89
congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)Inherited from D50-D89
endocrine, nutritional and metabolic diseases (E00-E88)Inherited from D50-D89
human immunodeficiency virus [HIV] disease (B20)Inherited from D50-D89
injury, poisoning and certain other consequences of external causes (S00-T88)Inherited from D50-D89
neoplasms (C00-D49)Inherited from D50-D89
symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)Inherited from D50-D89

Related Codes

Official

D70.0Congenital agranulocytosis D70.1Agranulocytosis secondary to cancer chemotherapy D70.3Neutropenia due to infection D70.4Cyclic neutropenia D70.8Other neutropenia

Includes

Official

agranulocytosisInherited from D70
decreased absolute neurophile count (ANC)Inherited from D70

Excludes 1

Official

neutropenic splenomegaly (D73.81)Inherited from D70
transient neonatal neutropenia (P61.5)Inherited from D70

Code First

Official

No Code First sequencing instructions are included in this display for D70.2. Check the code and parent instructions in the Code Book.

Use Additional

Official

code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)
code for any associated:Inherited from D70
fever (R50.81)Inherited from D70

Code Also

Official

, if applicable, mucositis (J34.81, K12.3-, K92.81, N76.81)Inherited from D70

Buddy Documentation Tip

HCC Buddy guidance

Document the offending medication, temporal relationship between drug initiation and neutropenia onset, absolute neutrophil count nadir, and response after drug discontinuation.

Record the adverse effect T-code for the specific medication, any infectious complications, and G-CSF use.

Note whether the medication was restarted or a substitute was used.

MEAT Support

HCC Buddy guidance

Document the offending medication, temporal relationship between drug initiation and neutropenia onset, absolute neutrophil count nadir, and response after drug discontinuation.

Record the adverse effect T-code for the specific medication, any infectious complications, and G-CSF use.

Note whether the medication was restarted or a substitute was used.

Audit Caution

HCC Buddy guidance

Always pair D70.2 with the appropriate adverse effect T-code identifying the causative medication.

Clozapine-associated agranulocytosis requires specific monitoring protocols — document compliance with mandated blood count monitoring.

Distinguish from dose-dependent medication effects (chemotherapy) which use D70.1.

Common Mistakes

HCC Buddy guidance

D70.1 (Agranulocytosis secondary to cancer chemotherapy) — expected dose-dependent effect versus idiosyncratic drug reaction

D70.8 (Other neutropenia) — non-drug-related acquired neutropenia

D70.9 (Neutropenia, unspecified) — should specify drug-induced cause when documented.

Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →

Is D70.2 an HCC code?

D70.2 is not in the CMS-HCC V28 or V24 community payment model. D70.2 has a separate mapping under the CMS-HCC ESRD model (HCC 47 (Disorders of Immunity)); the applicable result needs member context.

Code: D70.2
Description: Other drug-induced agranulocytosis
HCC (V28): No CMS-HCC V28 mapping
RAF reference coefficient: —
Billable: Yes
Payment year: 2026

HCC Category Mapping

ESRDHCC 47, Disorders of Immunity

Not separately weighted

These are source-labeled model coefficients, not member totals. A category may still be removed by hierarchy or model cleanup rules. Weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member context, hierarchy and cleanup rules, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains available for historical review.

Work D70.2 in the Code Book — tabular path, V28 RAF reference, and MEAT checklist →

MEAT review for D70.2

For D70.2, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule.

MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
EEvaluate: test results, medication response, or physical findings reviewed by the provider
AAssess: explicit mention in the assessment or plan with acknowledgment of status
TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Coder workflow notes

Get the V28 mapping + MEAT cheat sheet

One printable reference: check representative V28 mappings and the documentation reminders your note needs. Free, no card.

Free PDF. No card. Unsubscribe anytime.

What This Code Means

D70.2 is the ICD-10-CM diagnosis code for other drug-induced agranulocytosis. A low white blood cell count caused by medications other than chemotherapy drugs. D70.2 sits in the ICD-10-CM chapter for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (d50-d89), within the section covering other disorders of blood and blood-forming organs (d70-d77).

D70.2 has no mapping under the CMS-HCC V28 or V24 community payment models. D70.2 has a separate mapping under the CMS-HCC ESRD model (HCC 47 (Disorders of Immunity)); the applicable result needs member context. Do not assign V28 risk adjustment value from this page; verify the applicable model and payment year before using this code for risk adjustment.

Document the specific medication causing the agranulocytosis in the medical record for clarity.

HCC Buddy maintains structured V28 and V24 mapping, source-labeled coefficient references, and MEAT documentation criteria for D70.2 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

•Document the specific medication causing the agranulocytosis in the medical record for clarity
•Differentiate from D70.1 (chemotherapy-induced) by confirming the offending drug is not a cancer treatment

Clinical Significance

Other drug-induced agranulocytosis captures severe neutropenia caused by non-chemotherapy medications, including antithyroid drugs (methimazole, propylthiouracil), clozapine, sulfasalazine, dapsone, and certain antibiotics. This is an idiosyncratic reaction that can be life-threatening and requires immediate drug discontinuation. Unlike chemotherapy-induced neutropenia, it is unpredictable and not dose-dependent.

Documentation Requirements

✓Document the offending medication, temporal relationship between drug initiation and neutropenia onset, absolute neutrophil count nadir, and response after drug discontinuation.
✓Record the adverse effect T-code for the specific medication, any infectious complications, and G-CSF use.
✓Note whether the medication was restarted or a substitute was used.

Use Additional Code

code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)

Commonly Confused Codes

•D70.1 (Agranulocytosis secondary to cancer chemotherapy): expected dose-dependent effect versus idiosyncratic drug reaction
•D70.8 (Other neutropenia): non-drug-related acquired neutropenia
•D70.9 (Neutropenia, unspecified): should specify drug-induced cause when documented.